Closing out their review of endocrine therapy in HR+ metastatic breast cancer, panelists consider clinical trial data with selective estrogen receptor modulators [SERMs].
Eva M. Ciruelos Gil, MD, PhD: Lasofoxifene is not a SERD [selective estrogen receptor degraders], it’s a SERM [selective estrogen receptor modulator]. Based on any differences you’ve seen in the different drug pools, or your conclusions for SERDs and lasofoxifene data, do you see any different roles for this drug?
Sara M. Tolaney, MD, MPH: I think it’s being developed in a similar way. It seems as though the data that we saw yesterday were comparing lasofoxifene [Fablyn] with fulvestrant [Faslodex] in the ESR1-mutant population and showing pretty similar data. This may be a trend toward a benefit. But again, I think it’s an active agent that is well tolerated. I thought the data we saw at ASCO [American Society of Clinical Oncology Annual Meeting 2022] were quite impressive. This was the agent in combination with abemaciclib [Verzenio]. It is moving forward into registrational studies. As you point out, it is different. It’s a SERM, as opposed to a SERD, so I think it has a lot of potential because the abemaciclib combination data looked outstanding. We’ll have to see what happens.
Eva M. Ciruelos Gil, MD, PhD: Let’s see. Thank you very much, Sara.
Transcript edited for clarity.